The global adhesion barrier market is poised for significant growth, projected to expand from $0.7 billion in 2023 to $0.9 billion by 2028, at a compound annual growth rate (CAGR) of 7.4%. This upward trajectory is fueled by several key factors, including an aging global population, a surge in surgical procedures and sports-related injuries, and heightened awareness of adhesion formation complications.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=208132543

Market Drivers and Challenges

The primary driver propelling the adhesion barrier market’s growth is the increasing volume of surgeries and sports-related injuries worldwide. Adhesion formation is a common post-surgical complication, often necessitating repeat surgeries for treatment. As the number of surgeries rises, so does the demand for effective adhesion barriers to mitigate these complications.

However, the market faces a notable challenge: the reluctance of some surgeons to adopt adhesion barriers due to limited reliable clinical evidence supporting the safety and efficacy of currently available products. Additionally, stringent regulations have hindered technological innovations, further exacerbating the issue.

Geographical Landscape

While the adhesion barrier market is witnessing growth globally, the Asia-Pacific region is expected to experience the fastest expansion during the forecast period. Factors such as rapid economic growth, the presence of universal healthcare reimbursement policies, and an increasing disease prevalence are driving the demand for advanced medical technologies in this region.

Key Market Segments

The synthetic adhesion barrier product segment is anticipated to experience the highest growth rate during the forecast period, attributed to its resorbable nature and cost-effectiveness compared to natural adhesion barriers.

In terms of formulation, film-based adhesion barriers held the largest market share in 2022, owing to their wide availability, strong clinical evidence supporting their safety and efficacy, and ease of use.

Hospitals and clinics dominated the market in 2022, reflecting the high volume of surgical procedures performed in these settings.

Untapped Opportunities

Emerging markets in regions like Asia-Pacific, Latin America, and the Middle East and Africa present significant untapped opportunities for players in the adhesion barrier market. These regions have a large patient base for target indications, such as cardiovascular, orthopedic, general/abdominal, and gynecological disorders, coupled with an increasing number of surgical procedures being performed.

Key Players

Prominent players in the adhesion barrier market include Baxter International, Johnson & Johnson, Becton, Dickinson and Company, Integra LifeSciences, Anika Therapeutics, Atrium Medical Corporation, FzioMed, MAST Biosurgery, Innocoll, Betatech Medical, CorMatrix Cardiovascular, Inc., Terumo Corporation, BiosCompass, W.L.Gore & Associates, GUNZE Limited, Leader Biomedical, Xlynk Surgical, Luna Solutions, PlantTec Medical GmbH, Actamax Surgical Materials, LLC, Arc Medical Devices, INC., CG Bio INC., Seikagaku Corporation, Hangzhou Singclean Medical Products Co.,Ltd, and Allosource.

As the global healthcare landscape continues to evolve, the adhesion barrier market is poised to play a crucial role in mitigating post-surgical complications, driving innovation, and improving patient outcomes worldwide.

The global interventional oncology market is projected to experience robust growth in the coming years, driven by several key factors. Valued at $1.9 billion in 2020, this market is expected to reach $2.9 billion by 2026, growing at an impressive compound annual growth rate (CAGR) of 6.8%.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=203687164

The Rise of Minimally Invasive Cancer Treatments

A major driver of market growth is the increasing patient preference for minimally invasive procedures over traditional surgical methods. These advanced techniques offer numerous advantages, including fewer complications, shorter hospital stays, reduced pain and scarring, lower infection risks, and quicker recovery times. By leveraging cutting-edge technologies, interventional oncology enables precise tumor removal and tissue sampling for accurate cancer staging and treatment planning.

Addressing the Skill Gap

Despite the growing demand, a shortage of well-trained radiologists and oncologists skilled in interventional techniques poses a significant challenge. This scarcity is expected to be more pronounced in developing regions, potentially hindering market growth and patient access to these advanced cancer treatments.

Emerging Markets Hold Promise

Rapid economic development and increased healthcare spending in emerging economies like China, India, Brazil, and Mexico present a promising opportunity for the interventional oncology market. Rising cancer incidence rates and government initiatives to improve healthcare infrastructure in these regions are fueling demand for innovative cancer therapies.

Strengthening Clinical Evidence

While interventional oncology procedures are gaining traction, the market faces the challenge of limited clinical data supporting their therapeutic efficacy. Rigorous clinical trials and methodologies are crucial to establish these techniques as standard cancer care practices and drive further adoption.

Market Landscape and Key Players

The interventional oncology market is segmented by product (embolization devices, ablation devices, and support devices), procedure (thermal and non-thermal tumor ablation, chemoembolization, radioembolization, and embolization), cancer type (liver, lung, bone metastasis, and others), and end-users (hospitals, ambulatory surgery centers, and research institutes).

Major players in this market include Medtronic, Boston Scientific, BD, Terumo, Merit Medical, AngioDynamics, Johnson & Johnson, Teleflex, Cook Medical, and HealthTronics, among others. These companies are focused on strategies such as acquisitions, expansions, regulatory approvals, and reimbursement coverage to strengthen their market positions and product offerings.

Boston Scientific (US) dominated the global interventional oncology market in 2020. The company mainly focuses on growth strategies such as acquisitions and expansions to increase its market presence and product offerings. The company’s plan to acquire BTG will help expand its product offerings in chemoembolization, radioembolization, and ablation therapies. Boston Scientific constantly strives to gain regulatory and reimbursement approvals. As a part of its long-term growth strategy, the company invests in fast-growing markets as well as new markets by strengthening its position in the global healthcare market.

Medtronic (Ireland) held the second position in the global interventional oncology market in 2020. The company focuses on adopting various organic growth strategies like product launches & approvals and inorganic growth strategies, such as acquisitions and collaborations, to expand its presence and share in the interventional oncology market. In line with this, the company launched various tumor management products like OptiSphere Embolization Spheres and OsteoCool Rf Ablation Systems and received US FDA clearance, which helped it to expand its presence in the market.

Merit Medical (US) held the third position in the global interventional oncology market in 2020. The company offers a broad range of products integral to the interventional oncology market, which are used across regions such as North America, Europe, the Asia Pacific, Africa, and the Middle East for the minimally invasive treatment of cancers. The company mainly focuses on developing technologically innovative products to further strengthen its position in the interventional oncology market. The company offers non-radioactive embolic agents, radioactive embolic agents, and cryoablation products. The company has adopted organic and inorganic strategies to maintain its position in the interventional oncology market.

As the interventional oncology market continues to evolve, driven by technological advancements and increasing demand for minimally invasive cancer treatments, it holds significant promise for improving patient outcomes and quality of life.

The global oligonucleotide synthesis market is experiencing explosive growth, projected to surge from $8.8 billion in 2024 to a staggering $19.7 billion by 2029 at a compound annual growth rate of 17.5%. This meteoric rise is fueled by several key drivers.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=200829350

Driving Forces Behind the Market’s Ascent

• Escalating use of synthesized oligonucleotides in therapeutic and diagnostic applications, harnessing their potential to tackle a diverse array of neurological disorders, rare diseases, and gene therapy.
• Continuous technological advancements, such as next-generation sequencing (NGS) and the revolutionary CRISPR gene-editing tool, which are catalyzing demand for oligonucleotide synthesis.
• Burgeoning investments from governments and major industry players in life science research and synthetic biology, paving the way for groundbreaking discoveries.
• A crescendoing focus on precision and personalized medicine, underscoring the indispensable role of oligonucleotides in tailoring treatments to individual genetic profiles.

Opportunities on the Horizon

Emerging economies, such as China, India, Japan, Brazil, and Argentina, present fertile ground for market growth, attracting substantial investments from leading companies seeking to expand their footprint in these regions. For instance, in 2023, Merck KGaA, a German biotechnology giant, invested $76 million to bolster production capabilities for high-purity reagents in Nantong, China.

Challenges and Complexities

While the market’s prospects are bright, challenges persist. Achieving precise control over oligonucleotide length while minimizing impurities poses a significant hurdle. Additionally, the generation of harmful waste during synthesis is an environmental concern that demands innovative solutions. Furthermore, the efficient delivery of oligonucleotide drugs to specific targets remains a formidable obstacle, with researchers actively exploring novel strategies, such as positively charged cell-penetrating peptides, to enhance drug bioavailability.

Key Players Shaping the Landscape

Major players in the oligonucleotide synthesis market include Danaher Corporation, Thermo Fisher Scientific Inc., Merck KGaA, Eurofins Scientific, LGC Limited, Agilent Technologies, Inc., Kaneka Corporation, Maravai Lifesciences Holdings, Inc., Azenta, Inc., Twist Bioscience Corporation, and Genscript Biotech Corporation. In the therapeutic applications segment, prominent companies include Biogen Inc., Alnylam Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Astrazeneca, Astellas Pharma Inc., Jazz Pharmaceuticals Plc, Nippon Shinyaku, Co. Ltd., Ionis Pharmaceuticals, Inc., and Novartis AG.

As the oligonucleotide synthesis market continues its upward trajectory, fueled by scientific breakthroughs and a growing recognition of its transformative potential, it stands poised to reshape the landscape of therapeutics, diagnostics, and personalized medicine.

DANAHER CORPORATION (US)

Danaher is one of the key players in the oligonucleotide synthesis market. The company through its two major subsidiary Integrated DNA Technologies (IDT) and Cytiva offers various products such as predesigned and custom oligonucelotide probes, primers, as well as therapeutic oligonucleotides such as ASOs, apart from this the company provides reagents, consumables and equipments such as synthesizers for oligonucelotide synthesis. Geographically, the company operates in more than 50 countries across North America, Asia Pacific, Europe, the Middle East, and Africa. IDT and Cytiva uses organic strategies such as expansions and partnerships as their key growth strategies. In 2023, Integrated DNA Technologies (IDT) opened its therapeutic oligonucleotide manufacturing facility in Coralville, Iowa. This facility will produce reagents for cGMP cell & gene therapy, including single-guide RNAs and HDR donor oligos. In 2022, Cytiva partnered with General Biol (Anhui) Co., Ltd. a company from China to provide an integrated FlexFactory platform featuring the OligoProcess nucleic acid synthesis system, ÄKTAprocess purification system, Uniflux tangential flow filtration system, and other advanced technologies. This setup will allow General Biol (Anhui) Co., Ltd. to expand its oligonucleotide CDMO business.

THERMO FISHER SCIENTIFIC, INC. (US)

Thermo Fisher Scientific (US) held the second-largest share in the oligonucleotide synthesis market in 2023. This significant share is due to the pressnec of a strong product portfolio, including custom and predesigned primers, probes, DNA, and RNA oligos, as well as reagents and consumables. The company undertakes various organic and inorganic strategies to strengthen its position in the market. For instance, in 2021, Thermo Fisher Scientific entered in a strategic collaboration with the University of Sheffield aimed at developing workflows for the characterization and monitoring of complex oligonucleotide and mRNA products utilizing various technologies from Thermo Fisher and the research expertise of the University of Sheffield. The company also has a strong geographic presence and operates in more than 50 countries across the North America, Europe, Asia Pacific and the Latim America regions.

The global 3D cell culture market is experiencing significant growth, projected to reach $2.5 billion by 2028, expanding at a compound annual growth rate (CAGR) of 14.6% from 2023 to 2028. This growth is fueled by several key drivers and opportunities within the industry.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=191072847

Driving Forces:

1. Alternatives to Animal Testing: One of the primary drivers is the increasing focus on developing alternatives to animal testing in pharmaceutical and scientific research. 3D cell culture models provide a more physiologically relevant and predictive platform for studying drug efficacy and toxicity, reducing the reliance on animal models. Regulatory bodies are encouraging the adoption of these advanced in vitro models, spurring growth in the 3D cell culture industry.
2. Personalized Medicine: The rising demand for personalized medicine has led to an increased need for 3D cell culture techniques. These models offer a closer representation of human tissues and organs, allowing researchers to study the effects of drugs and potential toxicities in a more personalized and accurate manner.

Emerging Opportunities:

1. Microfluidics-based 3D Cell Culture: The emergence of microfluidics-based 3D cell culture presents a lucrative opportunity for the market. These microfluidic devices enable the creation of controlled microenvironments for cells, allowing the integration of multiple cell types and the development of complex cellular models that closely mimic in vivo conditions. Key players in the industry are collaborating to develop human disease models and organ-on-chip technologies, further driving the adoption of microfluidic-based 3D cell culture.
2. Technological Advancements: Continuous advancements in 3D cell culture technology, such as the development of new scaffolds, bioreactors, and imaging systems, are expected to drive market growth. Companies like Corning and Thermo Fisher Scientific are introducing innovative products to meet the evolving needs of researchers and pharmaceutical companies.

Challenges and Restraints:

1. High Costs: The high cost of implementing 3D cell culture technologies remains a significant challenge, particularly for smaller research groups and individual researchers. Instruments, consumables, and maintenance costs can range from a few thousand to several hundred thousand dollars, limiting the widespread adoption of these technologies.
2. Lack of Standardization: The lack of consistency and standardization in 3D cell culture products poses a challenge for the industry. Variability in cell culture, quality control issues, and the transition from small-scale to large-scale manufacturing can introduce variables that impact the consistency and reproducibility of results.

The 3D cell culture market is witnessing significant growth driven by the demand for alternatives to animal testing, personalized medicine, and the emergence of microfluidics-based technologies. However, addressing challenges such as high costs and lack of standardization will be crucial for the industry’s continued expansion and broader adoption of these advanced cell culture techniques.

The global patient handling equipment market is projected to experience robust growth in the coming years, driven by several key factors. According to recent estimates, this market was valued at $10.4 billion in 2022 and is expected to reach $14.0 billion by 2027, registering a compound annual growth rate (CAGR) of 6.2% during this period.

The latest report on this market provides an updated overview, including assessments across all segments from 2020 to 2027. It also offers insights into industry trends, technology analysis, pricing analysis, and patent analysis. Additionally, the report considers the impact of the ongoing economic recession on market sizing and provides qualitative insights on its regional impact.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=186358368

Fueling the growth of this market is a combination of factors, such as the growing number of geriatric and obese populations, the high risk of injuries to caregivers during manual patient handling, the rising number of patient admissions in hospitals, and the implementation of regulations and guidelines ensuring the safety of healthcare providers during manual lifting processes. However, the lack of proper training for caregivers in the efficient use of patient handling equipment remains a significant challenge hampering market growth.

Key Drivers and Opportunities

One of the primary drivers of this market is the growing number of geriatric and obese populations worldwide. The elderly population is more prone to fall-related injuries, leading to functional disabilities and a greater reliance on mobility equipment. Additionally, the increasing demand for home healthcare services is presenting a significant opportunity for market growth. Government regulations and guidelines aimed at reducing the duration and cost of healthcare treatments are promoting the shift towards nursing homes and home healthcare, which is more affordable than facility-based care.

Segmentation Insights

The patient transfer devices segment is expected to register the highest CAGR during the forecast period, attributed to the increased incidence of lifestyle diseases like obesity, the growing preference for home care among the obese population, and the rising adoption of ceiling lifts in bariatric patient handling practices. Additionally, the hospital segment accounted for the largest share of the market in 2021, driven by factors such as the rise in the geriatric population, the increase in the patient population, the rise in the number of injuries caused during patient handling processes, and the surge in the number of disabled people.

Regional Landscape

North America accounted for the second-largest share of the patient handling equipment market in 2021, owing to the growing number of elderly care facilities, the increasing number of hospitals and ambulatory centers, the rising geriatric population in the US and Canada, and high healthcare expenditure.

Competitive Landscape

The patient handling equipment market is dominated by several globally established players, including Arjo (Sweden), Baxter International Inc. (US), Savaria (Canada), Invacare Corporation (US), Stryker (US), Drive DeVilbiss Healthcare (US), Etac AB (Sweden), GF Health Products, Inc. (US), V. Guldmann A/S (Denmark), Joerns Healthcare LLC (US), Medline Industries, Inc. (US), Prism Medical UK Ltd. (UK), LINET (Czech Republic), Stiegelmeyer GmbH & Co. KG (Germany), Benmor Medical (UK), Malvetio Spa (Italy), and EZ Way, Inc. (US).

The global enteral feeding devices market is experiencing remarkable growth, fueled by the increasing prevalence of chronic diseases and the aging population. Valued at $4.0 billion in 2023, this market is projected to reach $5.6 billion by 2029, growing at a robust compound annual growth rate (CAGR) of 6.2%.

Enteral feeding devices play a crucial role in delivering essential nutrients directly into the digestive system, offering a lifeline to patients who cannot consume food orally due to various medical conditions. As the world’s population ages and the incidence of chronic illnesses rises, the demand for these devices is soaring.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=183623035

Driving Forces Behind the Growth

The rapid growth of the geriatric population and the accompanying rise in age-related chronic diseases are the primary drivers of this market’s expansion. With advances in healthcare and improved living standards, people are living longer, but they also face an increased risk of conditions that can impair their ability to swallow or maintain a healthy appetite.

Enteral feeding devices provide a reliable solution for delivering essential nutrients, preventing malnutrition, and promoting overall health in elderly patients. Additionally, the growing awareness among healthcare professionals and the public about the benefits of enteral feeding is contributing to its wider adoption.

Opportunities and Challenges

The market is rife with opportunities, particularly in the home care sector. Improvements in enteral feeding devices, such as quieter pumps, disposable feeding sets, and remote monitoring capabilities, have made them more user-friendly and portable for home use. As healthcare systems shift towards home-based care models, enteral feeding devices enable patients to receive essential nutrition in the comfort of their own homes, creating significant growth opportunities.

However, the market also faces challenges. The dearth of skilled professionals and endoscopy specialists trained in the proper placement, management, and monitoring of enteral feeding devices can create bottlenecks, potentially hindering market growth.

Competitive Landscape and Industry Ecosystem

The enteral feeding devices market is highly competitive, with new players entering and established companies vying for market share. This competition drives down prices as businesses strive to maintain profitability while keeping their offerings affordable. Consolidation within the enteral nutrition industry, particularly the rise of home care settings, creates larger entities with greater purchasing power, further pressuring smaller players.

Key players in the market include Fresenius SE & Co. KGAA, Cardinal Health, Inc., Nestlé S.A., Avanos Medical, Inc., Danone S.A., Becton, Dickinson and Company, B. Braun Melsungen AG, CONMED Corporation, Cook Medical, Moog Inc., Boston Scientific Corporation, Baxter International Inc., Vygon, and others.

Looking Ahead

As the world’s population continues to age and chronic diseases become more prevalent, the demand for enteral feeding devices is expected to surge. With ongoing advancements in technology and a growing emphasis on home-based care, this market is poised to play an increasingly vital role in delivering essential nutrition and improving the quality of life for patients worldwide.

The global protein expression market is expected to experience substantial growth in the coming years, projected to expand from $2.9 billion in 2022 to $5.4 billion by 2027 at a compound annual growth rate (CAGR) of 13.3%. This burgeoning market is driven by several key factors, including the increasing demand for protein biologics, particularly in the treatment of chronic diseases such as cancer, autoimmune disorders, and other serious conditions.

As the life science and biopharmaceutical industries continue to thrive, the focus on recombinant protein expression and the availability of investments for protein-based research are providing further impetus to the market’s growth. However, the high cost of protein expression reagents and instruments remains a restraining factor, potentially limiting adoption in certain areas.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=180323924

One of the notable trends shaping the market is the emergence of microfluidics, an advanced technique offering robust solutions for protein expression studies and analysis. Microfluidic technologies, such as droplet-based microfluidic (DBM) high-throughput screening and microfluidic antibody capture (MAC) chips, are enabling more efficient and precise evaluation of protein expression levels and protein modifications.

While the market faces challenges related to undesired post-translational modifications and the complexities of protein purification, the mammalian cell expression system segment continues to dominate, driven by its low cost and ease of use.

Geographically, North America currently leads the protein expression market, propelled by the region’s strong biotechnology and pharmaceutical industries, the prevalence of chronic disorders, and increased investments in protein-based therapeutics research.

Key players in the global protein expression market include Thermo Fisher Scientific, Merck KGaA, GenScript Biotech Corporation, Agilent Technologies, Danaher Corporation, Sartorius AG, Takara Bio, Bio-Rad Laboratories, Lonza Group AG, Promega Corporation, New England Biolabs, and Oxford Expression Technologies Ltd.

As the demand for protein biologics continues to surge and technological advancements unlock new possibilities, the protein expression market is poised for sustained growth, driving innovation and propelling the development of groundbreaking therapeutics.

Based on geography, the global protein expression market is segmented into Asia, Europe, North America, and Rest of the World (RoW). Of these, the Asian segment that includes the regional segments of China, India, Japan, and Rest of Asia (RoA) is expected to grow at the highest CAGR between 2013 and 2018. The growth in the Asian economies, particularly in China and India along with the increasing investments in biotechnology in Asia will be the major drivers for growth in the Asian protein expression market. In addition, the Asian region has witnessed an upward trend in the proteomics market over the past few years as many North American and European pharmaceutical drug manufacturers find it cost-effective to outsource their proteomics-based work to Asian manufacturers or set up their own manufacturing facilities in the Asian countries.

Thus, on account of the rise in demand of biologics, therapeutic proteins emerge as a lucrative revenue pocket. The demand for therapeutic proteins will handsomely reward investments made in the therapeutic protein industry. In the forecast period between 2013 and 2018, contract research organizations will provide generous returns on investments on account of the rising trend in outsourcing of research activities. Similarly, the economic developments in the Asian region will make the Asian countries one of the most lucrative revenue pockets in the global protein expression market. Investments made in the Asian proteomics industry will reap heavy dividends.

The market for Autoimmune Disease Diagnosis is experiencing rapid growth and is projected to expand from $4.1 billion in 2020 to $6.3 billion by 2025, increasing at an impressive 8.9% annual rate. Several key factors are fueling this market’s expansion.

Rising Autoimmune Disease Rates Drive Demand

Perhaps the biggest driver is the high and increasing prevalence of autoimmune conditions like rheumatoid arthritis, lupus, Sjögren’s syndrome and thyroiditis. As these diseases become more common, the need for accurate diagnostic tests grows correspondingly.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174826519

Greater Awareness Spurring Testing

Along with higher disease rates, increased public and medical awareness about autoimmune disorders is prompting more patients to seek testing and diagnosis. Extensive research into understanding and treating these conditions is also contributing to market growth.

Consumables Lead Product Segment

When analyzing the product landscape, the consumables and assay kits segment is expected to see the highest growth rates during the forecast period. This can be attributed to frequent new product launches and approvals in this category meeting rising testing demand.

Routine Tests Dominate Test Types

Among the various diagnostic test types, routine laboratory tests like blood work are estimated to experience the highest growth rates going forward. The widespread availability and affordable costs of these standard tests are key advantages driving adoption.

Europe Leads Regional Markets

Regionally, Europe represented the largest autoimmune disease diagnostic market in 2019, followed by Asia Pacific. Europe’s large population of aging patients susceptible to autoimmune conditions is a major factor underpinning the region’s market leadership.

Prominent Market Players

Major companies operating in this space include Thermo Fisher Scientific, Siemens, Abbott, Danaher, Bio-Rad, Grifols, Trinity Biotech and many others. With escalating demand, intense competition can be expected among these firms to supply innovative diagnostic products.

Siemens AG

Siemens AG (Germany) is among the leaders in the global autoimmune disease diagnosis market in 2018. The company offers its products in the healthcare industry through its business segment of diagnostics, under the Siemens Healthineers. The company is focused primarily on inorganic and organic strategies such as expansion and product launches/approvals. For instance, during December 2018, Siemens expanded its manufacturing unit situated in the Walpole, Mass, United States. The new facility manufactures tests for the immunoassay module of the Atellica Solution. R&D efforts at the site bring new tests to the in-vitro diagnostics market to help physicians diagnose, monitor, and treat diseases. Such development strengthens the position of the company in the market.

Abbott

Abbott (US) is another leading player in the autoimmune disease diagnosis market. The company recorded positive growth in its revenue in 2018, as compared to that of 2017. Moreover, in 2018, the company generated 35% of its total revenue from the United States. The company focuses on organic and inorganic growth, such as collaboration, and product launches/product approval, to strengthen its position in the market. For instance, in 2017, the company entered into a partnership with North West London Pathology for the supply of analytical equipment and consumables, including Abbotts Alinity ci and Alinity h series diagnostics instruments.

In summary, the autoimmune disease diagnostic market is experiencing robust growth propelled by the increasing prevalence of these conditions, greater awareness spurring more testing, and a product mix catering to rising demand. As the population continues aging and autoimmune disease rates climb further, this market’s expansion trajectory seems poised to continue over the coming years.

The US healthcare/hospital food services market is witnessing robust expansion, projected to surge from $13.2 billion in 2021 to $22.8 billion by 2026, driven by a remarkable 11.5% compound annual growth rate (CAGR). This burgeoning market is fueled by several key factors, including the rising prevalence of chronic diseases, heightened awareness about the pivotal role of nutrition in healthcare, and a growing emphasis on enhancing the patient dining experience.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=170935372

Chronic ailments such as heart disease, type 2 diabetes, and obesity have become increasingly prevalent, underscoring the urgent need for improved dietary practices. Hospitals and healthcare facilities are recognizing the transformative power of “food as medicine,” prompting them to offer customized meal options tailored to diverse dietary requirements. Simultaneously, restrictions on outside food items and the cost-effectiveness of outsourcing food services have further propelled the market’s expansion.

However, challenges persist, including the reluctance of outpatient clients to pay for food services, pricing complexities, and staffing shortages. Nonetheless, the market’s future remains promising, buoyed by the growing adoption of innovative and diverse menus catering to patients’ evolving preferences, such as gluten-free, vegetarian, and vegan options.

Navigating the intricate landscape of patient nutritional needs poses a formidable challenge for healthcare food service providers. Factors like dental problems, dysphagia, addiction, dementia, depression, and loneliness can profoundly impact patients’ appetites and willingness to consume nourishing meals, necessitating personalized care approaches.

Key players in the US healthcare/hospital food services market include industry giants like Compass Group plc, Sodexo, Aramark, Elior Group, and Healthcare Services Group, Inc., among others. These companies are leveraging strategic acquisitions and collaborations to bolster their market foothold and enhance their culinary and operational excellence.

Sodexo is the second-leading player in the US healthcare/hospital food services market. Sodexo provides catering, facilities management, employee benefits, and personal home services. Sodexo provides quality food services to companies, hospitals, schools, universities, and a range of other organizations. Its expertise also includes retail services, food delivery, meal and food vouchers, as well as digital food ordering services and apps.  Sodexo offers healthy, varied, balanced meals with seasonal produce while balancing the use of natural resources with clients’ operating contexts and guests budgets. The company offers three different service styles, namely, tray line, bedside host, and room service. Sodexo has strengthened its customer base in food services across the globe through inorganic growth strategies such as acquisitions and partnerships. The company is planning to include 33% of plant-based dishes in its menus by 2025. For this initiative, the teams at Sodexo have designed an on-site production space, which is focused on reinventing the supply of vegetables for the preparation of vegetarian and vegan dishes.

Aramark is the third-leading player in the US healthcare/hospital food services market. Aramark is a global provider of food, facilities, and uniform services to education, healthcare, business & industry, and sports, leisure & corrections clients. The company operates its business in three segments, namely, Food and Support Services United States, Food and Support Services International, and Uniform and Career Apparel. The company’s Food and Support Services segments manage various interrelated services, including food, hospitality, procurement, and facility services for schools, colleges, and universities; healthcare and senior living facilities; businesses, sports, entertainment, and recreational venues; conference & convention centers; national & state parks; and correctional institutes. The company provides a wide range of non-clinical food and food-related support services to approximately 573 healthcare and senior living clients and more than 651 facilities across the globe. The company’s food-related services include patient food and nutrition, retail food, environmental services, and procurement services.

As the healthcare landscape continues to evolve, the US healthcare/hospital food services market stands poised to play an increasingly pivotal role in promoting holistic patient well-being, underscoring the profound link between nourishment and healing.

The global digital diabetes management market is experiencing meteoric growth, projected to soar from $18.9 billion in 2023 to a staggering $35.8 billion by 2028, at a compound annual growth rate (CAGR) of 13.6%. This burgeoning industry is driven by the ever-increasing prevalence of diabetes worldwide and the corresponding demand for innovative, technologically advanced solutions to manage this chronic condition effectively.

Spearheading this revolution are groundbreaking advancements in artificial intelligence (AI) and connected devices. AI algorithms are revolutionizing diabetes care, enabling predictive models for risk assessment, optimizing resource utilization, and enhancing glycemic control. Pioneers like Medtronic, Abbott, and Dexcom are at the forefront of this AI-powered transformation, introducing cutting-edge devices such as artificial pancreas systems, continuous glucose monitoring (CGM) systems, and smart insulin pumps.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144725893

However, the high costs of these advanced devices and the lack of reimbursement policies in developing countries remain significant barriers to widespread adoption. With prices ranging from $4,500 to $6,500 for insulin pumps and $1,000 to $1,400 for CGM systems, these solutions remain out of reach for many patients, particularly in low-income regions.

Despite these challenges, the escalating global health expenditure due to diabetes presents a compelling opportunity for market growth. The International Diabetes Federation (IDF) estimates that diabetes-related health expenditure will reach a staggering $1.03 trillion by 2030, representing a substantial 11.5% of total global health spending.

The market landscape is dominated by prominent players like Medtronic, B. Braun Melsungen AG, Dexcom, Abbott Laboratories, F. Hoffmann-La Roche, Insulet Corporation, and Tandem Diabetes Care, among others. These companies are at the forefront of innovation, leveraging state-of-the-art technologies, diversified product portfolios, and robust global networks to drive market penetration.

Dexcom, Inc. (US)

In 2022, Dexcom was the market leader for digital diabetes management. With its flagship Dexcom products, the company dominated the market for continuous glucose monitoring systems. CGM systems like the Dexcom G7 and Integrated Continuous Glucose Monitoring (iCGM) System, Dexcom G6 Continuous Glucose Monitoring (CGM) System, Dexcom G5 Mobile CGM System, and Dexcom One are among the company’s product offerings. Company has 242 manufacturing and distribution facilities located all over the world. To increase its market share in digital diabetes management, Dexcom focuses on alliances, contracts, and acquisitions. Dexcom has partnered with a number of businesses in recent years to integrate its CGM system with additional insulin pumps. The company emphasises on growing its presence across the world, which gives it access to more resources for production and better customer service. For instance, the company established new offices in Scotland and Canada. The company also grew its footprint in additional regions, including Europe, Australia, the Middle East, and Africa.

Medtronic (Ireland)

The company’s broad product portfolio, which includes insulin pumps, smart glucose metres, CGM systems, mobile applications, data management software, and services, has been associated with its leading position in this market. The business is present throughout the world, including North America, Latin America, Europe, Africa, the Middle East, and Asia Pacific. MiniMed 780 Systems, MiniMed 670 Systems, Guardian Connect CGM Systems, CareLinkdiabetes Personal Software, and StartRight Programmes are all part of Medtronic’s digital portfolio for managing diabetes. The company emphasises on product launching, innovative products and establishing partnerships and alliances with other market participants in order to maintain its leading position in the market.

Abbott Laboratories (US)

In 2022, Abbott Laboratories held the third-position in the market for digital diabetes management. The company provides CGM systems, smart insulin pens, smart insulin pumps, smart insulin patches, and data management software. It also offers connected glucose metres. Abbott provides a range of digital CGM devices for managing diabetes and software platforms that are popular with end users all over the world under its flagship brand, freestyle libre. The geographic reach of Abbott Laboratories also extends to the Middle East, Africa, Asia, and North America. To keep up its market dominance, the company mainly focuses on product launches and alliances and collaborations. In October 2022, the company launched freestyle libre 3 CGM that has contributed significantly in its revenue.

Looking ahead, the smart insulin pen segment is poised for the highest growth, fueled by increasing demand for personalized and patient-centric devices, as well as the need to prevent needle-stick injuries. Additionally, the digital diabetes management apps segment is projected to experience rapid expansion, with diabetes and blood glucose tracking apps leading the charge.

As the digital diabetes management market continues its upward trajectory, it holds the promise of transforming diabetes care, empowering patients with cutting-edge solutions, and ultimately improving outcomes for millions of individuals affected by this chronic condition worldwide.